 Megan Turner
Concepts (151)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Hypoxia-Ischemia, Brain | 2 | 2024 | 50 | 1.530 |
Why?
| | Acute Kidney Injury | 3 | 2025 | 874 | 1.410 |
Why?
| | HIV Infections | 20 | 2026 | 3195 | 1.330 |
Why?
| | Tuberculosis | 3 | 2026 | 284 | 0.940 |
Why?
| | Hypothermia, Induced | 2 | 2024 | 96 | 0.920 |
Why?
| | AIDS-Related Opportunistic Infections | 1 | 2026 | 130 | 0.890 |
Why?
| | Anti-HIV Agents | 6 | 2026 | 912 | 0.870 |
Why?
| | HIV-1 | 5 | 2026 | 908 | 0.860 |
Why?
| | Infant, Premature, Diseases | 1 | 2025 | 113 | 0.820 |
Why?
| | Ductus Arteriosus, Patent | 1 | 2023 | 52 | 0.740 |
Why?
| | Infant, Newborn, Diseases | 1 | 2023 | 115 | 0.710 |
Why?
| | Viral Load | 6 | 2026 | 526 | 0.450 |
Why?
| | CD4 Lymphocyte Count | 4 | 2026 | 280 | 0.440 |
Why?
| | HIV Integrase Inhibitors | 3 | 2021 | 79 | 0.430 |
Why?
| | Brain | 2 | 2024 | 2969 | 0.420 |
Why?
| | Biomarkers | 2 | 2024 | 4302 | 0.380 |
Why?
| | Infant, Newborn | 4 | 2025 | 6465 | 0.360 |
Why?
| | Antitubercular Agents | 2 | 2024 | 208 | 0.350 |
Why?
| | Magnetic Resonance Imaging | 1 | 2024 | 3916 | 0.340 |
Why?
| | Brazil | 3 | 2026 | 179 | 0.330 |
Why?
| | CD4-CD8 Ratio | 2 | 2019 | 23 | 0.270 |
Why?
| | Continuity of Patient Care | 3 | 2018 | 297 | 0.250 |
Why?
| | Glucuronosyltransferase | 1 | 2026 | 18 | 0.240 |
Why?
| | Proportional Hazards Models | 3 | 2025 | 1330 | 0.230 |
Why?
| | Anti-Retroviral Agents | 2 | 2018 | 251 | 0.220 |
Why?
| | Arylamine N-Acetyltransferase | 1 | 2024 | 8 | 0.220 |
Why?
| | Infant, Extremely Premature | 1 | 2025 | 68 | 0.220 |
Why?
| | Coinfection | 1 | 2026 | 143 | 0.210 |
Why?
| | Erythropoietin | 1 | 2025 | 100 | 0.210 |
Why?
| | Prospective Studies | 3 | 2026 | 8078 | 0.210 |
Why?
| | Hepatitis A Virus Cellular Receptor 1 | 1 | 2024 | 43 | 0.210 |
Why?
| | Lipocalin-2 | 1 | 2024 | 80 | 0.200 |
Why?
| | Cardiovascular Diseases | 3 | 2024 | 2191 | 0.200 |
Why?
| | Humans | 27 | 2026 | 145785 | 0.200 |
Why?
| | HIV Seropositivity | 1 | 2024 | 119 | 0.190 |
Why?
| | Indomethacin | 1 | 2023 | 76 | 0.190 |
Why?
| | Multiple Organ Failure | 1 | 2023 | 120 | 0.190 |
Why?
| | Interleukin-18 | 1 | 2024 | 234 | 0.190 |
Why?
| | Female | 20 | 2026 | 79045 | 0.180 |
Why?
| | Male | 18 | 2026 | 73012 | 0.180 |
Why?
| | Benzoxazines | 2 | 2021 | 31 | 0.180 |
Why?
| | Gestational Age | 1 | 2025 | 990 | 0.170 |
Why?
| | Adult | 18 | 2026 | 40882 | 0.170 |
Why?
| | Bipolar Disorder | 1 | 2024 | 291 | 0.170 |
Why?
| | Reverse Transcriptase Inhibitors | 2 | 2020 | 87 | 0.170 |
Why?
| | Genotype | 1 | 2026 | 1857 | 0.170 |
Why?
| | Creatinine | 1 | 2023 | 515 | 0.170 |
Why?
| | Weight Gain | 3 | 2021 | 561 | 0.160 |
Why?
| | Risk Factors | 6 | 2025 | 10919 | 0.160 |
Why?
| | Healthcare Disparities | 2 | 2025 | 736 | 0.160 |
Why?
| | Ischemia | 1 | 2023 | 422 | 0.160 |
Why?
| | Multivariate Analysis | 1 | 2024 | 1547 | 0.160 |
Why?
| | Anti-Inflammatory Agents, Non-Steroidal | 1 | 2023 | 346 | 0.150 |
Why?
| | Noncommunicable Diseases | 1 | 2020 | 21 | 0.150 |
Why?
| | Retrospective Studies | 10 | 2025 | 17330 | 0.140 |
Why?
| | Mood Disorders | 1 | 2020 | 144 | 0.140 |
Why?
| | Southeastern United States | 3 | 2025 | 37 | 0.140 |
Why?
| | Infant, Premature | 1 | 2023 | 620 | 0.140 |
Why?
| | Substance Abuse, Intravenous | 1 | 2019 | 127 | 0.130 |
Why?
| | Hepatitis C, Chronic | 1 | 2019 | 153 | 0.130 |
Why?
| | No-Show Patients | 1 | 2017 | 3 | 0.130 |
Why?
| | Treatment Outcome | 4 | 2026 | 11794 | 0.130 |
Why?
| | Body Mass Index | 3 | 2025 | 2447 | 0.130 |
Why?
| | Liver Cirrhosis | 1 | 2019 | 288 | 0.130 |
Why?
| | Diabetes Mellitus | 1 | 2025 | 1101 | 0.120 |
Why?
| | Middle Aged | 15 | 2025 | 36309 | 0.120 |
Why?
| | Health Literacy | 1 | 2018 | 186 | 0.120 |
Why?
| | Stress Disorders, Post-Traumatic | 1 | 2023 | 890 | 0.110 |
Why?
| | Cohort Studies | 7 | 2024 | 6033 | 0.110 |
Why?
| | Kidney | 1 | 2023 | 1497 | 0.110 |
Why?
| | Medroxyprogesterone Acetate | 1 | 2015 | 33 | 0.110 |
Why?
| | Contraceptives, Oral, Hormonal | 1 | 2015 | 30 | 0.110 |
Why?
| | Marijuana Abuse | 1 | 2017 | 214 | 0.100 |
Why?
| | Ambulatory Care Facilities | 3 | 2024 | 269 | 0.100 |
Why?
| | Contraceptive Agents, Female | 1 | 2015 | 80 | 0.100 |
Why?
| | Medication Adherence | 1 | 2018 | 540 | 0.100 |
Why?
| | Tennessee | 3 | 2019 | 57 | 0.100 |
Why?
| | Socioeconomic Factors | 1 | 2018 | 1327 | 0.100 |
Why?
| | Marijuana Use | 1 | 2017 | 222 | 0.100 |
Why?
| | Patient Compliance | 1 | 2017 | 588 | 0.090 |
Why?
| | Cannabis | 1 | 2020 | 510 | 0.090 |
Why?
| | Liver Diseases | 1 | 2016 | 305 | 0.090 |
Why?
| | Sexually Transmitted Diseases | 1 | 2015 | 168 | 0.090 |
Why?
| | Lipopolysaccharide Receptors | 1 | 2013 | 88 | 0.090 |
Why?
| | Neoplasms | 2 | 2019 | 2913 | 0.090 |
Why?
| | Patient-Centered Care | 1 | 2017 | 547 | 0.090 |
Why?
| | Kidney Diseases | 1 | 2016 | 426 | 0.090 |
Why?
| | Pharmacogenetics | 2 | 2024 | 175 | 0.090 |
Why?
| | Cyclopropanes | 2 | 2021 | 84 | 0.080 |
Why?
| | Alkynes | 2 | 2021 | 67 | 0.070 |
Why?
| | Interleukin-6 | 1 | 2013 | 780 | 0.070 |
Why?
| | Young Adult | 6 | 2024 | 14254 | 0.070 |
Why?
| | Caribbean Region | 1 | 2026 | 29 | 0.060 |
Why?
| | Central America | 1 | 2026 | 28 | 0.060 |
Why?
| | South America | 1 | 2026 | 56 | 0.060 |
Why?
| | Mental Disorders | 1 | 2015 | 1171 | 0.060 |
Why?
| | Glutathione Transferase | 1 | 2024 | 92 | 0.050 |
Why?
| | Adult Survivors of Child Abuse | 1 | 2024 | 31 | 0.050 |
Why?
| | Affective Symptoms | 1 | 2024 | 53 | 0.050 |
Why?
| | Tuberculosis, Pulmonary | 1 | 2024 | 127 | 0.050 |
Why?
| | Incidence | 2 | 2024 | 2934 | 0.050 |
Why?
| | Metabolic Diseases | 1 | 2024 | 114 | 0.050 |
Why?
| | HIV | 1 | 2024 | 251 | 0.050 |
Why?
| | Academic Medical Centers | 1 | 2025 | 554 | 0.040 |
Why?
| | United States | 4 | 2023 | 16126 | 0.040 |
Why?
| | Adolescent | 4 | 2024 | 22577 | 0.040 |
Why?
| | Oxazines | 1 | 2020 | 37 | 0.040 |
Why?
| | Heterocyclic Compounds, 3-Ring | 1 | 2020 | 44 | 0.040 |
Why?
| | Age Factors | 2 | 2018 | 3346 | 0.040 |
Why?
| | Lymphopenia | 1 | 2019 | 62 | 0.040 |
Why?
| | Guinea Pigs | 1 | 2019 | 159 | 0.040 |
Why?
| | Obesity | 1 | 2013 | 3118 | 0.040 |
Why?
| | Aged | 4 | 2019 | 26217 | 0.030 |
Why?
| | Antiretroviral Therapy, Highly Active | 1 | 2020 | 279 | 0.030 |
Why?
| | Pyridones | 1 | 2020 | 209 | 0.030 |
Why?
| | Piperazines | 1 | 2020 | 375 | 0.030 |
Why?
| | Referral and Consultation | 1 | 2023 | 869 | 0.030 |
Why?
| | Cause of Death | 1 | 2019 | 472 | 0.030 |
Why?
| | Polymorphism, Single Nucleotide | 1 | 2024 | 2181 | 0.030 |
Why?
| | Kaplan-Meier Estimate | 1 | 2019 | 971 | 0.030 |
Why?
| | Hepatitis C | 1 | 2019 | 256 | 0.030 |
Why?
| | Mass Screening | 1 | 2025 | 1361 | 0.030 |
Why?
| | Appointments and Schedules | 1 | 2017 | 96 | 0.030 |
Why?
| | Marijuana Smoking | 1 | 2020 | 249 | 0.030 |
Why?
| | Social Class | 1 | 2018 | 264 | 0.030 |
Why?
| | Models, Theoretical | 1 | 2019 | 560 | 0.030 |
Why?
| | RNA, Viral | 1 | 2019 | 693 | 0.030 |
Why?
| | Self Report | 1 | 2020 | 876 | 0.030 |
Why?
| | Sexual and Gender Minorities | 1 | 2019 | 265 | 0.030 |
Why?
| | Residence Characteristics | 1 | 2018 | 375 | 0.030 |
Why?
| | Depression | 1 | 2024 | 1559 | 0.030 |
Why?
| | Odds Ratio | 1 | 2017 | 1083 | 0.030 |
Why?
| | Comorbidity | 1 | 2019 | 1662 | 0.030 |
Why?
| | Poverty | 1 | 2018 | 529 | 0.030 |
Why?
| | Antiviral Agents | 1 | 2019 | 769 | 0.020 |
Why?
| | RNA | 1 | 2020 | 912 | 0.020 |
Why?
| | CD4-Positive T-Lymphocytes | 1 | 2020 | 1146 | 0.020 |
Why?
| | Chronic Disease | 1 | 2019 | 1812 | 0.020 |
Why?
| | Chemokine CCL3 | 1 | 2013 | 26 | 0.020 |
Why?
| | Receptors, Tumor Necrosis Factor, Type I | 1 | 2013 | 80 | 0.020 |
Why?
| | Sexual Behavior | 1 | 2017 | 495 | 0.020 |
Why?
| | Solubility | 1 | 2013 | 240 | 0.020 |
Why?
| | Ambulatory Care | 1 | 2017 | 610 | 0.020 |
Why?
| | Risk | 1 | 2015 | 923 | 0.020 |
Why?
| | C-Reactive Protein | 1 | 2013 | 423 | 0.020 |
Why?
| | Inflammation Mediators | 1 | 2013 | 507 | 0.020 |
Why?
| | Longitudinal Studies | 1 | 2017 | 2968 | 0.020 |
Why?
| | Obesity, Morbid | 1 | 2013 | 293 | 0.020 |
Why?
| | Follow-Up Studies | 1 | 2017 | 5428 | 0.020 |
Why?
| | Risk Assessment | 1 | 2016 | 3752 | 0.010 |
Why?
| | Animals | 1 | 2019 | 38106 | 0.010 |
Why?
|
|
Turner's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|